The report, sponsored by ARM, Intellia Therapeutics, and CRISPR Therapeutics, and endorsed by former MEP Maria Teresa Giménez Barbat, discusses the commercial, clinical, regulatory, and ethical landscape and framework for the development of therapeutic for genome editing in Europe.
Leave a Reply